Citations to this article
Grit S. Herter-Sprie, … , Alec C. Kimmelman, Kwok-Kin Wong
Published June 16, 2016
Citation Information: JCI Insight. 2016;1(9):e87415. https://doi.org/10.1172/jci.insight.87415.
Citation Information: JCI Insight. 2016;1(9):e87415. https://doi.org/10.1172/jci.insight.87415.
Abstract
Radiation therapy (RT), a critical modality in the treatment of lung cancer, induces direct tumor cell death and augments tumor-specific immunity. However, despite initial tumor control, most patients suffer from locoregional relapse and/or metastatic disease following RT. The use of immunotherapy in non–small-cell lung cancer (NSCLC) could potentially change this outcome by enhancing the effects of RT. Here, we report significant (up to 70% volume reduction of the target lesion) and durable (up to 12 weeks) tumor regressions in conditional
Authors
Grit S. Herter-Sprie, Shohei Koyama, Houari Korideck, Josephine Hai, Jiehui Deng, Yvonne Y. Li, Kevin A. Buczkowski, Aaron K. Grant, Soumya Ullas, Kevin Rhee, Jillian D. Cavanaugh, Neermala Poudel Neupane, Camilla L. Christensen, Jan M. Herter, G. Mike Makrigiorgos, F. Stephen Hodi, Gordon J. Freeman, Glenn Dranoff, Peter S. Hammerman, Alec C. Kimmelman, Kwok-Kin Wong
Total citations by year
Citation information
Citations to this article (105)
| Title and authors | Publication | Year |
|---|---|---|
|
IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization
Guangzhao L, Xin W, Miaoqing W, Wenjuan M, Ranyi L, Zhizhong P, Rongxin Z, Gong C |
Cancer Immunology, Immunotherapy : CII | 2025 |
|
免疫治疗时代广泛期小细胞肺癌的放疗进展
CHEN T, YANG Y, HAN H, LIU D, YUAN Y, XU L |
Chinese Journal of Lung Cancer | 2025 |
|
Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review)
Li Q, Cai YQ, Shao LH, Qi YX, Guo LY, Song HX, Dong YM, Wei SH |
Oncology Letters | 2025 |
|
FGFR inhibition augments anti-PD1 efficacy in FGFR3 mutant bladder cancer by abrogating immune suppression.
Atsushi Okato, Takanobu Utsumi, Michela Ranieri, Xingnan Zheng, Mi Zhou, Luiza Pereira, Ting Chen, Yuki Kita, Di Wu, HYO JIN LEE, Andrew Gdowski, John Raupp, Ujjawal Manocha, Alison Chafitz, Fiona Sherman, Janaye Stephens, Sara Wobker, Tracy Rose, Matthew Milowsky, Jeffrey Damrauer, Kwok-Kin Wong, William Kim |
Journal of Clinical Investigation | 2024 |
|
Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer.
Zhu Q, Dai Q, Zhao L, Zheng C, Li Q, Yuan Z, Li L, Xie Z, Qiu Z, Huang W, Liu G, Zu X, Chu B, Jiang Y |
Cell Death and Disease | 2024 |
|
Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.
Liu Y, Jiang X, Wu Y, Yu H |
Heliyon | 2024 |
|
Double-dose osimertinib combined with intrathecal injection of pemetrexed improves the efficacy of EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis: case report and literature review.
Zhong W, Wu L, Huang L, Wang J, Shi H, Wu S |
Frontiers in Oncology | 2024 |
|
Definitive chemoradiotherapy induces T-cell-inflamed tumor microenvironment in unresectable locally advanced esophageal squamous cell carcinoma.
Habu T, Kumagai S, Bando H, Fujisawa T, Mishima S, Kotani D, Nakamura M, Hojo H, Sakashita S, Kinoshita T, Yano T, Mitsunaga S, Nishikawa H, Koyama S, Kojima T |
Journal of Gastroenterology | 2024 |
|
Tumor-intrinsic IFNα and CXCL10 are critical for immunotherapeutic efficacy by recruiting and activating T lymphocytes in tumor microenvironment
Cheng CC, Chang J, Ho AS, Sie ZL, Peng CL, Wang C, Dev K, Chang CC |
Cancer Immunology, Immunotherapy | 2024 |
|
A good response to anti-PD-1 monoclonal antibody plus SBRT in a patient with PD-L1-negative recurrent advanced esophageal cancer: a long-term follow-up case report of a possible abscopal effect
Hai T, Liu J, Lai J, Zhou L |
Frontiers in Oncology | 2024 |
|
Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
Jaing TH, Wang YL, Chiu CC |
Pharmaceuticals | 2024 |
|
Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group
Nguyen NP, Page BR, Giap H, Dahbi Z, Vinh-Hung V, Gorobets O, Mohammadianpanah M, Motta M, Portaluri M, Arenas M, Bonet M, Lara PC, Kim L, Dutheil F, Natoli E, Loganadane G, Lehrman D, Bose S, Kaur S, Blanco SC, Chi A |
Cancers | 2024 |
|
The Optimal Radiotherapy Strategy for Patients With Small Cell Lung Cancer and Brain Metastasis: A Retrospective Analysis
Zeng Q, Chu X, Xiao G, Zhang J, Zhang Y, Long B, Yang L, Tan Z, Zhou R |
CNS Neuroscience & Therapeutics | 2024 |
|
Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors
Bhatt V, Lan T, Wang W, Kong J, Lopes EC, Wang J, Khayati K, Raju A, Rangel M, Lopez E, Hu ZS, Luo X, Su X, Malhotra J, Hu W, Pine SR, White E, Guo JY |
Cell Death and Disease | 2023 |
|
Prognostic impact of PD-L1 and TIGIT expression in non-small cell lung cancer following concurrent chemo-radiotherapy
Mori M, Kanayama M, Kuwata T, Manabe T, Nemoto Y, Nishizawa N, Oyama R, Matsumiya H, Nabe Y, Taira A, Takenaka M, Yoneda K, Kuroda K, Tanaka F |
Scientific Reports | 2023 |
|
Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma.
Li J, Chen Y, Fan Y, Wang H, Mu W, Liu X |
Discover. Oncology | 2023 |
|
Posttranslational regulation of liver kinase B1 in human cancer
Hu L, Liu M, Tang B, Li Q, Pan BS, Xu C, Lin HK |
The Journal of biological chemistry | 2023 |
|
Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies.
Glasner A, Rose SA, Sharma R, Gudjonson H, Chu T, Green JA, Rampersaud S, Valdez IK, Andretta ES, Dhillon BS, Schizas M, Dikiy S, Mendoza A, Hu W, Wang ZM, Chaudhary O, Xu T, Mazutis L, Rizzuto G, Quintanal-Villalonga A, Manoj P, de Stanchina E, Rudin CM, Pe'er D, Rudensky AY |
Nature Immunology | 2023 |
|
Mechanistic rationales for combining immunotherapy with radiotherapy
Chi A, Nguyen NP |
Frontiers in immunology | 2023 |
|
Non-POU Domain-Containing Octomer-Binding (NONO) protein expression and stability promotes the tumorigenicity and activation of Akt/MAPK/β-catenin pathways in human breast cancer cells
Lone BA, Siraj F, Sharma I, Verma S, Karna SK, Ahmad F, Nagar P, Sachidanandan C, Pokharel YR |
Cell communication and signaling : CCS | 2023 |
|
Radiotherapy and Immunotherapy in Lung Cancer
Hsieh K, Dickstein DR, Runnels J, Lehrer EJ, Rosenzweig K, Hirsch FR, Samstein RM |
Biomedicines | 2023 |
|
Ablative radiotherapy improves survival but does not cure autochthonous mouse models of prostate and colorectal cancer.
Schmidt DR, Gramatikov IMT, Sheen A, Williams CL, Hurwitz M, Dodge LE, Holupka E, Kiger WS 3rd, Cornwall-Brady MR, Huang W, Mak HH, Cormier KS, Condon C, Dane Wittrup K, Yilmaz ÖH, Stevenson MA, Down JD, Floyd SR, Roper J, Vander Heiden MG |
2023 | |
|
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
König D, Savic Prince S, Hayoz S, Zens P, Berezowska S, Jochum W, Stauffer E, Braunersreuther V, Trachsel B, Thierstein S, Mark M, Schmid S, Curioni-Fontecedro A, Addeo A, Opitz I, Guckenberger M, Früh M, Betticher DC, Ris HB, Stupp R, Rothschild SI, Bubendorf L, Pless M |
ESMO Open | 2023 |
|
Ultra-High Dose-Rate Proton FLASH Improves Tumor Control
Shukla S, Saha T, Rama N, Acharya A, Le T, Bian F, Donovan J, Tan LA, Vatner R, Kalinichenko V, Mascia A, Perentesis JP, Kalin TV |
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology | 2023 |
|
Safety and efficacy of thoracic radiotherapy combined with chemo-immunotherapy in patients with extensive-stage small cell lung cancer: a multicenter retrospective analysis
Cai Z, Gu X, Xie J, Cheng D, Chen J, Cheng J, Ye J, Lv T |
Translational Lung Cancer Research | 2023 |
|
Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio
Lu Q, Yan W, Zhu A, Tubin S, Mourad WF, Yang J |
Clinical and Translational Radiation Oncology | 2023 |
|
Modulation of CD8+ T Cell Responses by Radiotherapy—Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors
Jeon SH, Song C, Eom KY, Kim IA, Kim JS |
International journal of molecular sciences | 2023 |
|
The role of radiotherapy in tumor immunity and the potential of PET/CT in detecting the expression of PD-1/PD-L1.
Shen LF, Fu ZM, Zhou SH |
Japanese Journal of Radiology | 2023 |
|
How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation
M Milic, M Mondini, E Deutsch |
Cancers | 2022 |
|
Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases
T Pierret, N Giaj-Levra, A Toffart, F Alongi, D Moro-Sibilot, E Gobbini |
Frontiers in Oncology | 2022 |
|
PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer
Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, Kroemer G |
OncoImmunology | 2022 |
|
The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis
Chu X, Niu L, Xiao G, Peng H, Deng F, Liu Z, Wu H, Yang L, Tan Z, Li Z, Zhou R |
Frontiers in immunology | 2022 |
|
Impact of Previous Local Treatment for Brain Metastases on Response to Molecular Targeted Therapy in BRAF-Mutant Melanoma Brain Metastasis: A Systematic Review and Meta-Analysis
Liao G, Fu Y, Arooj S, Khan M, Li X, Yan M, Li Z, Yang H, Zheng T, Xu R |
Frontiers in Oncology | 2022 |
|
Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system
Weigert A, Zheng X, Nenzel A, Turkowski K, Günther S, Strack E, Sirait-Fischer E, Elwakeel E, Kur IM, Nikam VS, Valasarajan C, Winter H, Wissgott A, Voswinkel R, Grimminger F, Brüne B, Seeger W, Pullamsetti SS, Savai R |
Nature Communications | 2022 |
|
Influence of chemoradiation on the immune microenvironment of cervical cancer patients.
Herter JM, Kiljan M, Kunze S, Reinscheid M, Ibruli O, Cai J, Niu L, Heßelmann I, Trommer M, Herter-Sprie GS, Köhler C, Marnitz S |
2022 | |
|
Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches
Chang CH, Chang YC |
International journal of environmental research and public health | 2022 |
|
Effects of Photon Radiation on DNA Damage, Cell Proliferation, Cell Survival, and Apoptosis of Murine and Human Mesothelioma Cell Lines
Keam S, MacKinnon KM, D'Alonzo RA, Gill S, Ebert MA, Nowak AK, Cook AM |
Advances in Radiation Oncology | 2022 |
|
PD-L1: Biological mechanism, function, and immunotherapy in gastric cancer
Zhang Y, Yang Y, Chen Y, Lin W, Chen X, Liu J, Huang Y, Wang H, Teng L |
Frontiers in immunology | 2022 |
|
Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
Rajeev-Kumar G, Pitroda SP |
Neoplasia (New York, N.Y.) | 2022 |
|
Stereotactic Body Radiotherapy and Immunotherapy for Older Patients with Oligometastases: A Proposed Paradigm by the International Geriatric Radiotherapy Group
Nguyen NP, Ali A, Vinh-Hung V, Gorobets O, Chi A, Mazibuko T, Migliore N, Vasileiou M, Lehrman D, Mohammadianpanah M, Javadinia SA, Loganadane G, Basu T, Bose S, Karlsson U, Giap H |
Cancers | 2022 |
|
Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
Chen Z, Duan X, Qiao S, Zhu X |
Cancer Medicine | 2022 |
|
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
A Chi, X He, L Hou, NP Nguyen, G Zhu, RB Cameron, JM Lee |
Cancers | 2021 |
|
Combination therapy: Future directions of immunotherapy in small cell lung cancer
W Huang, JJ Chen, R Xing, YC Zeng |
Translational oncology | 2021 |
|
A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma
B Fitzgerald, KA Connolly, C Cui, E Fagerberg, DL Mariuzza, NI Hornick, GG Foster, I William, JF Cheung, NS Joshi |
2021 | |
|
Improved Immunotherapy Efficacy by Vascular Modulation
EL Newport, AR Pedrosa, A Njegic, KM Hodivala-Dilke, JM Muñoz-Félix |
Cancers | 2021 |
|
Effect of CMNa combined with radiotherapy on the tumor immune microenvironment of mouse cervical cancer cell transplantation tumor model
L Li, W Shi, J Zhou |
Bioengineered | 2021 |
|
Pharmacologic inhibition of ataxia telangiectasia and Rad3‐related (ATR) in the treatment of head and neck squamous cell carcinoma
P Karukonda, D Odhiambo, Y Mowery |
Molecular Carcinogenesis | 2021 |
|
Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer
Y Ban, GJ Markowitz, Y Zou, D Ramchandani, J Kraynak, J Sheng, SB Lee, ST Wong, NK Altorki, D Gao, V Mittal |
2021 | |
|
Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
B Li, C Jiang, L Pang, B Zou, M Ding, X Sun, J Yu, L Wang |
Frontiers in immunology | 2021 |
|
Hypofractionated Low-Dose Radiotherapy Combined with Immune Checkpoint Inhibition in Metastatic Solid Tumors
D Li, W Zhu, J Zhou, M Peng, Q Geng, X Pu, M Wang, H Jiang |
OncoTargets and therapy | 2021 |
|
Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
Y Kong, Y Ma, X Zhao, J Pan, Z Xu, L Zhang |
Frontiers in Oncology | 2021 |
|
Immune Resistance in Lung Adenocarcinoma
M Spella, GT Stathopoulos |
Cancers | 2021 |
|
Identification of Autophagy Related circRNA-miRNA-mRNA-Subtypes Network With Radiotherapy Responses and Tumor Immune Microenvironment in Non-small Cell Lung Cancer
L Fan, B Li, Z Li, L Sun |
Frontiers in Genetics | 2021 |
|
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy
K Koikawa, S Kibe, F Suizu, N Sekino, N Kim, TD Manz, BJ Pinch, D Akshinthala, A Verma, G Gaglia, Y Nezu, S Ke, C Qiu, K Ohuchida, Y Oda, TH Lee, B Wegiel, JG Clohessy, N London, S Santagata, GM Wulf, M Hidalgo, SK Muthuswamy, M Nakamura, NS Gray, XZ Zhou, KP Lu |
Cell | 2021 |
|
Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
D Marcus, RI Lieverse, C Klein, A Abdollahi, P Lambin, LJ Dubois, A Yaromina |
Cancers | 2021 |
|
Current Prospects for Treatment of Solid Tumors via Photodynamic, Photothermal, or Ionizing Radiation Therapies Combined with Immune Checkpoint Inhibition (A Review)
S Anand, T Chan, T Hasan, E Maytin |
Pharmaceuticals (Basel, Switzerland) | 2021 |
|
Step-by-Step Immune Activation for Suicide Gene Therapy Reinforcement
I Alekseenko, A Kuzmich, L Kondratyeva, S Kondratieva, V Pleshkan, E Sverdlov |
International journal of molecular sciences | 2021 |
|
Uncloaking Breast Tumor Neoantigens with Radiation
JH Newman, N Bhardwaj |
Trends in Immunology | 2021 |
|
Irradiation Mediates IFNα and CXCL9 Expression in Non-Small Cell Lung Cancer to Stimulate CD8+ T Cells Activity and Migration toward Tumors
CC Cheng, YF Chang, AS Ho, ZL Sie, JS Chang, CL Peng, CC Chang |
Biomedicines | 2021 |
|
Irradiation Suppresses IFNγ-Mediated PD-L1 and MCL1 Expression in EGFR-Positive Lung Cancer to Augment CD8+ T Cells Cytotoxicity
CI Wang, YF Chang, ZL Sie, AS Ho, JS Chang, CL Peng, CC Cheng |
Cells | 2021 |
|
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer
J Deng, A Thennavan, I Dolgalev, T Chen, J Li, A Marzio, JT Poirier, DH Peng, M Bulatovic, S Mukhopadhyay, H Silver, E Papadopoulos, V Pyon, C Thakurdin, H Han, F Li, S Li, H Ding, H Hu, Y Pan, V Weerasekara, B Jiang, ES Wang, I Ahearn, M Philips, T Papagiannakopoulos, A Tsirigos, E Rothenberg, J Gainor, GJ Freeman, CM Rudin, NS Gray, PS Hammerman, M Pagano, JV Heymach, CM Perou, N Bardeesy, KK Wong |
2021 | |
|
Combining radiation therapy and immunotherapy for lung cancers: a narrative review
C Modi, L Berim, L Isserow, J Malhotra, M Patel, J Langenfeld, J Aisner, D Almeldin, SK Jabbour |
2021 | |
|
KRAS mutation: from undruggable to druggable in cancer
L Huang, Z Guo, F Wang, L Fu |
Signal Transduction and Targeted Therapy | 2021 |
|
The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
L Wen, F Tong, R Zhang, L Chen, Y Huang, X Dong |
Frontiers in Oncology | 2021 |
|
Enhancing the Bystander and Abscopal Effects to Improve Radiotherapy Outcomes
V de Araújo Farias, I Tovar, R del Moral, F O'Valle, J Expósito, FJ Oliver, JM de Almodóvar |
Frontiers in Oncology | 2020 |
|
Adoptive Cell Therapy: A Novel and Potential Immunotherapy for Glioblastoma
J Wang, F Shen, Y Yao, L Wang, Y Zhu, J Hu |
Frontiers in Oncology | 2020 |
|
Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
H Sato, N Okonogi, T Nakano |
International Journal of Clinical Oncology | 2020 |
|
Novel Radiation Therapy Paradigms and Immunomodulation: Heresies and Hope
S Dutt, MM Ahmed, BW Loo, S Strober |
Seminars in radiation oncology | 2020 |
|
Chemoradioimmunotherapy of inoperable stage III non-small cell lung cancer: immunological rationale and current clinical trials establishing a novel multimodal strategy
L Käsmann, C Eze, J Taugner, O Roengvoraphoj, M Dantes, NS Schmidt-Hegemann, S Schiopu, C Belka, F Manapov |
Radiation Oncology | 2020 |
|
Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer LF Shen, SH Zhou, Y Guo |
OncoTargets and therapy | 2020 |
|
Targeting PD-L1 in non-small cell lung cancer using CAR T cells
M Liu, X Wang, W Li, X Yu, P Flores-Villanueva, ZY Xu-Monette, L Li, M Zhang, KH Young, X Ma, Y Li |
Oncogenesis | 2020 |
|
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
L Galluzzi, J Humeau, A Buqué, L Zitvogel, G Kroemer |
Nature Reviews Clinical Oncology | 2020 |
|
The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray
ES Gruber, G Oberhuber, D Pils, T Stork, K Sinn, S Gruber, R Nica, D Kolmer, SD Turner, M Schlederer, J Widder, W Doerr, B Teleky, L Kenner |
Cancers | 2020 |
|
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
J Narits, H Tamm, J Jaal |
Clinical and Translational Radiation Oncology | 2020 |
|
Immune-Based Approaches for the Treatment of Pediatric Malignancies
KR Bosse, RG Majzner, CL Mackall, JM Maris |
Annual Review of Cancer Biology | 2020 |
|
Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer
HJ Han, YR Li, M Roach, R Aggarwal |
Therapeutic advances in medical oncology | 2020 |
|
Radiotherapy for non-small cell lung cancer in the immunotherapy era: the opportunity and challenge—a narrative review
WY Xia, W Feng, CC Zhang, YJ Shen, Q Zhang, W Yu, XW Cai, XL Fu |
Translational Lung Cancer Research | 2020 |
|
Enhancing the efficacy of immunotherapy using radiotherapy
S Keam, S Gill, MA Ebert, AK Nowak, AM Cook |
IBMS BoneKEy | 2020 |
|
Combining immunotherapy and radiotherapy in lung cancer: a promising future?
J Zhou, Q Huang, Z Huang, J Li |
Journal of Thoracic Disease | 2020 |
|
Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now
MG Kris, C Faivre-Finn, T Kordbacheh, J Chaft, J Luo, A Tsao, S Swisher |
American Society of Clinical Oncology Educational Book | 2020 |
|
Immune targets in the tumor microenvironment treated by radiotherapy
OM Ozpiskin, L Zhang, JJ Li |
Theranostics | 2019 |
|
Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy
JS Bowers, SR Bailey, MP Rubinstein, CM Paulos, ER Camp |
Oncology Reviews | 2019 |
|
90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin’s Lymphoma
R Hernandez, KL Walker, JJ Grudzinski, E Aluicio-Sarduy, R Patel, CD Zahm, AN Pinchuk, CF Massey, AN Bitton, RJ Brown, PM Sondel, ZS Morris, JW Engle, CM Capitini, JP Weichert |
2019 | |
|
IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer
F Ritzmann, C Jungnickel, G Vella, A Kamyschnikow, C Herr, D Li, MM Menger, A Angenendt, M Hoth, A Lis, R Bals, C Beisswenger |
Scientific Reports | 2019 |
|
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent anti-tumor activity following radiation
Frank P Vendetti, Pooja Karukonda, David Clump, Troy Teo, Ronald Lalonde, Katriana Nugent, Matthew Ballew, Brian F Kiesel, Jan, H Beumer, Saumendra N. Sarkar, Thomas P. Conrads, Mark J O'Connor, Robert L. Ferris, Phuoc Tran, Greg M Delgoffe, Christopher Bakkenist |
Journal of Clinical Investigation | 2018 |
|
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells
U Testa, G Castelli, E Pelosi |
Cancers | 2018 |
|
Autochthonous murine models for the study of smoker and never-smoker associated lung cancers
EA Akbay, J Kim |
Translational Lung Cancer Research | 2018 |
|
BET bromodomain inhibition cooperates with PD-1 blockade to facilitate antitumor response in Kras-mutant non-small cell lung cancer
DO Adeegbe, S Liu, M Hattersley, M Bowden, CW Zhou, S Li, R Vlahos, M Grondine, I Dolgalev, E Ivanova, MM Quinn, P Gao, PS Hammerman, JE Bradner, JA Diehl, AK Rustgi, AJ Bass, A Tsirigos, GJ Freeman, H Chen, KK Wong |
Cancer immunology research | 2018 |
|
Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma
I Martinez-Zubiaurre, AJ Chalmers, T Hellevik |
Frontiers in immunology | 2018 |
|
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
J Gong, TQ Le, E Massarelli, AE Hendifar, R Tuli |
Journal for ImmunoTherapy of Cancer | 2018 |
|
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Y Yan, AB Kumar, H Finnes, SN Markovic, S Park, RS Dronca, H Dong |
Frontiers in immunology | 2018 |
|
Combining immunotherapy with radiation therapy in thoracic oncology
SN Badiyan, MC Roach, MD Chuong, SR Rice, NE Onyeuku, J Remick, S Chilukuri, E Glass, P Mohindra, CB Simone |
Journal of Thoracic Disease | 2018 |
|
Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?
P Lamichhane, N Amin, M Agarwal, N Lamichhane |
Medicines | 2018 |
|
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
A Maity, R Mick, AC Huang, SM George, MD Farwell, JN Lukens, AT Berman, TC Mitchell, J Bauml, LM Schuchter, M OHara, LL Lin, A Demichele, JP Christodouleas, NB Haas, DM Patsch, SM Hahn, AJ Minn, EJ Wherry, RH Vonderheide |
British Journal of Cancer | 2018 |
|
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib
S Liu, S Li, J Hai, X Wang, T Chen, MM Quinn, P Gao, Y Zhang, H Ji, D Cross, KK Wong |
Clinical cancer research | 2018 |
|
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
C Lazzari, N Karachaliou, A Bulotta, M Viganó, A Mirabile, E Brioschi, M Santarpia, L Gianni, R Rosell, V Gregorc |
Therapeutic advances in medical oncology | 2018 |
|
The DNA damage response in immunotherapy and radiation
RM Samstein, N Riaz |
Advances in Radiation Oncology | 2018 |
|
Kras and Tumor Immunity: Friend or Foe?
J Cullis, S Das, D Bar-Sagi |
Cold Spring Harbor Perspectives in Medicine | 2017 |
|
The Future of Radiobiology
DG Kirsch, M Diehn, AH Kesarwala, A Maity, MA Morgan, JK Schwarz, R Bristow, S Demaria, I Eke, RJ Griffin, D Haas-Kogan, GS Higgins, AC Kimmelman, RJ Kimple, IM Lombaert, L Ma, B Marples, F Pajonk, CC Park, D Schaue, PT Tran, H Willers, BG Wouters, EJ Bernhard |
JNCI Journal of the National Cancer Institute | 2017 |
|
Combining radiotherapy with immunotherapy: the past, the present and the future
EJ van Limbergen, DK de Ruysscher, VO Pimentel, D Marcus, M Berbee, A Hoeben, N Rekers, J Theys, A Yaromina, LJ Dubois, P Lambin |
British Journal of Radiology | 2017 |
|
DNA Damage and Repair Biomarkers of Immunotherapy Response
KW Mouw, MS Goldberg, PA Konstantinopoulos, AD D'Andrea |
Cancer Discovery | 2017 |
|
Radiation alters PD-L1/NKG2D ligand levels in lung cancer cells and leads to immune escape from NK cell cytotoxicity via IL-6-MEK/Erk signaling pathway
MJ Shen, LJ Xu, L Yang, Y Tsai, PC Keng, Y Chen, SO Lee, Y Chen |
Oncotarget | 2017 |
|
Synergy of WEE1 and mTOR Inhibition in Mutant KRAS -Driven Lung Cancers
J Hai, S Liu, L Bufe, K Do, T Chen, X Wang, C Ng, S Li, MS Tsao, GI Shapiro, KK Wong |
Clinical cancer research | 2017 |
|
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
N Shaverdian, AE Lisberg, K Bornazyan, D Veruttipong, JW Goldman, SC Formenti, EB Garon, P Lee |
The Lancet Oncology | 2017 |
|
Uncovering the immune tumor microenvironment in non-small cell lung cancer to understand response rates to checkpoint blockade and radiation
JE Schoenhals, SN Seyedin, C Anderson, ED Brooks, YR Li, AI Younes, S Niknam, A Li, HB Barsoumian, MA Cortez, JW Welsh |
Translational Lung Cancer Research | 2007 |
